Context: Penile tumescence during endoscopic urological surgeries is a rare but problematic complication that can lead to postponement of the surgery. This study was done to assess the efficacy of ultra-low-dose intracavernosal adrenaline in the management of intraoperative penile erection.

Subjects And Methods: Between January 2015 and December 2019, all the patients who developed significant penile tumescence during endourology procedures following regional anesthesia were included. Twenty patients required intervention. They were given half milliliter of solution containing 2.5 μg of adrenaline with insulin syringe. Baseline systolic and diastolic blood pressure, heart rate, and oxygen saturation were noted and were recorded at 1, 2, 3, 4, and 5 min after giving adrenaline. Time to achieve complete detumescence and any other related complications were also noted.

Results: Penile detumescence was achieved in 2.6 ± 0.47 min in all the patients. There was an increase in heart rate from baseline value which increased to maximum by 3 min and returned back to baseline by 5 min. Systolic and diastolic blood pressure remained unchanged.

Conclusion: All the patients achieved penile detumescence without any significant adverse effects after receiving intracavernosal injection of ultra-low-dose adrenaline.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428094PMC
http://dx.doi.org/10.4103/aer.AER_25_20DOI Listing

Publication Analysis

Top Keywords

efficacy ultra-low-dose
8
ultra-low-dose intracavernosal
8
intracavernosal adrenaline
8
intraoperative penile
8
penile tumescence
8
systolic diastolic
8
diastolic blood
8
blood pressure
8
heart rate
8
penile detumescence
8

Similar Publications

Background: Morphine analgesic tolerance (MAT) limits the clinical application of morphine in the management of chronic pain. IIK7 is a melatonin type 2 (MT2) receptor agonist known to have antioxidant properties. Oxidative stress is recognized as a critical factor in MAT.

View Article and Find Full Text PDF

Background: Single-pill combinations (SPCs) of three low-dose antihypertensive drugs can improve hypertension control but are not widely available. A key issue for any combination product is the contribution of each component to efficacy and tolerability. This trial compared a new triple SPC called GMRx2, containing telmisartan, amlodipine, and indapamide, with dual combinations of components for efficacy and safety.

View Article and Find Full Text PDF
Article Synopsis
  • This study tested an ultra-low-dose estriol vaginal gel (0.005%) to see if it could prevent urinary tract infections (UTIs) in postmenopausal women with genitourinary syndrome of menopause.
  • The clinical trial involved 108 women who were divided into two groups: one received the estriol gel, while the other got a placebo gel, and they were monitored for 24 weeks.
  • Results showed a 26% lower rate of UTIs in the group using estriol compared to placebo, indicating the gel is both safe and effective in reducing UTI occurrences and improving vaginal health.
View Article and Find Full Text PDF

Objectives: Evidence suggests ethnicity-specific differences in postmenopausal symptoms, highlighting the need for therapies that are efficacious across different ethnicities. We evaluated the efficacy of an ultra-low dose combination of 0.5 mg estradiol and 0.

View Article and Find Full Text PDF

Small-molecule prodrug nanoassembly technology with a unique advantage in off-target toxicity reduction has been widely used for antitumor drug delivery. However, prodrug activation remains a rate-limiting step for exerting therapeutic actions, which requires to quickly reach the minimum valid concentrations of free drugs. Fortunately, we find that a natural compound (BL-193) selectively improves the chemotherapy sensitivity of breast cancer cells to podophyllotoxin (PPT) at ineffective dose concentrations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!